The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis

BACKGROUND: Currently, nivolumab and ipilimumab are the most widely used immune checkpoint inhibitors. We performed a meta-analysis to evaluate the efficacy and treatment-related adverse events (TRAEs) of nivolumab plus ipilimumab therapy in cancer treatment. METHODS: We examined data from PubMed, W...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:World J Surg Oncol
Main Authors: Chen, Jingjie, Li, Shengnan, Yao, Qigu, Du, Nannan, Fu, Xiaojun, Lou, Yuanmei, Wang, Mengru, Mao, Feiyan, Mao, Danyi, Khadaroo, Parikshit Asutosh, Tang, Yingying
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7334852/
https://ncbi.nlm.nih.gov/pubmed/32620130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12957-020-01933-5
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados